Risk assessment and triage strategy of cervical cancer primary screening on HPV integration status: 5-year follow-up of a prospective cohort study
Objective: We investigated the relation between man papillomavirus (HPV) integration status and the immediate risk of cervical intraepithelial neoplasia (CIN), as well as the triage strategy based on HPV integration test. Methods: 4086 women aged 20 to 65 years in China were enrolled in 2015 for a p...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Journal of the National Cancer Center |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S266700542400084X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850137375933464576 |
|---|---|
| author | Xun Tian Danhui Weng Ye Chen Yi Wang Xiao Li Xin Wang Chen Cao Danni Gong Zhen Zeng Qiongyan Wu Xueqian Wang Peng Wu Lu Fan Qinghua Zhang Hui Wang Zheng Hu Xiaodong Cheng Ding Ma |
| author_facet | Xun Tian Danhui Weng Ye Chen Yi Wang Xiao Li Xin Wang Chen Cao Danni Gong Zhen Zeng Qiongyan Wu Xueqian Wang Peng Wu Lu Fan Qinghua Zhang Hui Wang Zheng Hu Xiaodong Cheng Ding Ma |
| author_sort | Xun Tian |
| collection | DOAJ |
| description | Objective: We investigated the relation between man papillomavirus (HPV) integration status and the immediate risk of cervical intraepithelial neoplasia (CIN), as well as the triage strategy based on HPV integration test. Methods: 4086 women aged 20 to 65 years in China were enrolled in 2015 for a prospective, population-based, clinical observational study to evaluate the triage performance of HPV integration. Cervical exfoliated cells were collected for HPV testing and cytologic test. If high-risk HPV was positive, HPV integration test was performed at baseline, 2-year and 5-year follow-up. Results: At baseline, HPV integration was positively correlated with the severity of cervical pathology, ranging from 5.0% (15/301) in normal diagnosis, 6.9% (4/58) in CIN1, 31.0% (9/29) in CIN2, 70% (14/20) in CIN3, and 100% (2/2) in cervical cancer (P < 0.001). Compared with cytology, HPV integration exhibits comparable sensitivity and negative predictive value for the diagnosis of CIN3+, higher specificity (92.8% [90.2%–95.4%] vs. 75.5% [71.2%–79.8%], P < 0.001) and higher positive predictive value (36.4% [22.1%–50.6%] vs. 15.2% [8.5%–21.8%], P < 0.001). HPV integration testing strategy yielded a significantly lower colposcopy referral rate than cytology strategy (10.7% [44/410] vs. 27.3% [112/410], P < 0.001). The HPV integration-negative group exhibited the lowest immediate risk for CIN3+ (1.6%) and accounted for the largest proportion of the total population (89.3%), when compared with the normal cytology group (risk, 1.7%; proportion, 72.7%). Conclusion: As a key molecular basis for the development of cervical cancer, HPV integration might be a promising triage strategy for HPV-positive patients. |
| format | Article |
| id | doaj-art-2d958522cbe94339971deea4c6053c71 |
| institution | OA Journals |
| issn | 2667-0054 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of the National Cancer Center |
| spelling | doaj-art-2d958522cbe94339971deea4c6053c712025-08-20T02:30:51ZengElsevierJournal of the National Cancer Center2667-00542024-12-014431131710.1016/j.jncc.2024.08.001Risk assessment and triage strategy of cervical cancer primary screening on HPV integration status: 5-year follow-up of a prospective cohort studyXun Tian0Danhui Weng1Ye Chen2Yi Wang3Xiao Li4Xin Wang5Chen Cao6Danni Gong7Zhen Zeng8Qiongyan Wu9Xueqian Wang10Peng Wu11Lu Fan12Qinghua Zhang13Hui Wang14Zheng Hu15Xiaodong Cheng16Ding Ma17Department of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; National Clinical Research Center for Obstetrics and Gynecology, Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Department of Obstetrics and Gynecology, Academician expert workstation, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; National Clinical Research Center for Obstetrics and Gynecology, Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Gynecology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Department of Obstetrics and Gynecology, The Affiliated Panyu Central Hospital of Guangzhou Medical University, Guangzhou, ChinaDepartment of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaDepartment of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; National Clinical Research Center for Obstetrics and Gynecology, Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Obstetrics and Gynecology, Academician expert workstation, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Obstetrics and Gynecology, Academician expert workstation, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Obstetrics and Gynecology, Academician expert workstation, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaDepartment of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; National Clinical Research Center for Obstetrics and Gynecology, Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; National Clinical Research Center for Obstetrics and Gynecology, Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Department of Gynecology and Obstetrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaMaternal and Child Health and Family Planning Service Center of Longyou County, Quzhou, ChinaDepartment of Obstetrics and Gynecology, Academician expert workstation, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, China; Corresponding authors.Department of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; National Clinical Research Center for Obstetrics and Gynecology, Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Department of Gynecologic Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China; Corresponding authors.Department of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, China; Corresponding authors.Department of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; National Clinical Research Center for Obstetrics and Gynecology, Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Corresponding authors.Objective: We investigated the relation between man papillomavirus (HPV) integration status and the immediate risk of cervical intraepithelial neoplasia (CIN), as well as the triage strategy based on HPV integration test. Methods: 4086 women aged 20 to 65 years in China were enrolled in 2015 for a prospective, population-based, clinical observational study to evaluate the triage performance of HPV integration. Cervical exfoliated cells were collected for HPV testing and cytologic test. If high-risk HPV was positive, HPV integration test was performed at baseline, 2-year and 5-year follow-up. Results: At baseline, HPV integration was positively correlated with the severity of cervical pathology, ranging from 5.0% (15/301) in normal diagnosis, 6.9% (4/58) in CIN1, 31.0% (9/29) in CIN2, 70% (14/20) in CIN3, and 100% (2/2) in cervical cancer (P < 0.001). Compared with cytology, HPV integration exhibits comparable sensitivity and negative predictive value for the diagnosis of CIN3+, higher specificity (92.8% [90.2%–95.4%] vs. 75.5% [71.2%–79.8%], P < 0.001) and higher positive predictive value (36.4% [22.1%–50.6%] vs. 15.2% [8.5%–21.8%], P < 0.001). HPV integration testing strategy yielded a significantly lower colposcopy referral rate than cytology strategy (10.7% [44/410] vs. 27.3% [112/410], P < 0.001). The HPV integration-negative group exhibited the lowest immediate risk for CIN3+ (1.6%) and accounted for the largest proportion of the total population (89.3%), when compared with the normal cytology group (risk, 1.7%; proportion, 72.7%). Conclusion: As a key molecular basis for the development of cervical cancer, HPV integration might be a promising triage strategy for HPV-positive patients.http://www.sciencedirect.com/science/article/pii/S266700542400084XHuman papillomavirusCervical cancer screeningHPV integrationColposcopyCervical intraepithelial neoplasia |
| spellingShingle | Xun Tian Danhui Weng Ye Chen Yi Wang Xiao Li Xin Wang Chen Cao Danni Gong Zhen Zeng Qiongyan Wu Xueqian Wang Peng Wu Lu Fan Qinghua Zhang Hui Wang Zheng Hu Xiaodong Cheng Ding Ma Risk assessment and triage strategy of cervical cancer primary screening on HPV integration status: 5-year follow-up of a prospective cohort study Journal of the National Cancer Center Human papillomavirus Cervical cancer screening HPV integration Colposcopy Cervical intraepithelial neoplasia |
| title | Risk assessment and triage strategy of cervical cancer primary screening on HPV integration status: 5-year follow-up of a prospective cohort study |
| title_full | Risk assessment and triage strategy of cervical cancer primary screening on HPV integration status: 5-year follow-up of a prospective cohort study |
| title_fullStr | Risk assessment and triage strategy of cervical cancer primary screening on HPV integration status: 5-year follow-up of a prospective cohort study |
| title_full_unstemmed | Risk assessment and triage strategy of cervical cancer primary screening on HPV integration status: 5-year follow-up of a prospective cohort study |
| title_short | Risk assessment and triage strategy of cervical cancer primary screening on HPV integration status: 5-year follow-up of a prospective cohort study |
| title_sort | risk assessment and triage strategy of cervical cancer primary screening on hpv integration status 5 year follow up of a prospective cohort study |
| topic | Human papillomavirus Cervical cancer screening HPV integration Colposcopy Cervical intraepithelial neoplasia |
| url | http://www.sciencedirect.com/science/article/pii/S266700542400084X |
| work_keys_str_mv | AT xuntian riskassessmentandtriagestrategyofcervicalcancerprimaryscreeningonhpvintegrationstatus5yearfollowupofaprospectivecohortstudy AT danhuiweng riskassessmentandtriagestrategyofcervicalcancerprimaryscreeningonhpvintegrationstatus5yearfollowupofaprospectivecohortstudy AT yechen riskassessmentandtriagestrategyofcervicalcancerprimaryscreeningonhpvintegrationstatus5yearfollowupofaprospectivecohortstudy AT yiwang riskassessmentandtriagestrategyofcervicalcancerprimaryscreeningonhpvintegrationstatus5yearfollowupofaprospectivecohortstudy AT xiaoli riskassessmentandtriagestrategyofcervicalcancerprimaryscreeningonhpvintegrationstatus5yearfollowupofaprospectivecohortstudy AT xinwang riskassessmentandtriagestrategyofcervicalcancerprimaryscreeningonhpvintegrationstatus5yearfollowupofaprospectivecohortstudy AT chencao riskassessmentandtriagestrategyofcervicalcancerprimaryscreeningonhpvintegrationstatus5yearfollowupofaprospectivecohortstudy AT dannigong riskassessmentandtriagestrategyofcervicalcancerprimaryscreeningonhpvintegrationstatus5yearfollowupofaprospectivecohortstudy AT zhenzeng riskassessmentandtriagestrategyofcervicalcancerprimaryscreeningonhpvintegrationstatus5yearfollowupofaprospectivecohortstudy AT qiongyanwu riskassessmentandtriagestrategyofcervicalcancerprimaryscreeningonhpvintegrationstatus5yearfollowupofaprospectivecohortstudy AT xueqianwang riskassessmentandtriagestrategyofcervicalcancerprimaryscreeningonhpvintegrationstatus5yearfollowupofaprospectivecohortstudy AT pengwu riskassessmentandtriagestrategyofcervicalcancerprimaryscreeningonhpvintegrationstatus5yearfollowupofaprospectivecohortstudy AT lufan riskassessmentandtriagestrategyofcervicalcancerprimaryscreeningonhpvintegrationstatus5yearfollowupofaprospectivecohortstudy AT qinghuazhang riskassessmentandtriagestrategyofcervicalcancerprimaryscreeningonhpvintegrationstatus5yearfollowupofaprospectivecohortstudy AT huiwang riskassessmentandtriagestrategyofcervicalcancerprimaryscreeningonhpvintegrationstatus5yearfollowupofaprospectivecohortstudy AT zhenghu riskassessmentandtriagestrategyofcervicalcancerprimaryscreeningonhpvintegrationstatus5yearfollowupofaprospectivecohortstudy AT xiaodongcheng riskassessmentandtriagestrategyofcervicalcancerprimaryscreeningonhpvintegrationstatus5yearfollowupofaprospectivecohortstudy AT dingma riskassessmentandtriagestrategyofcervicalcancerprimaryscreeningonhpvintegrationstatus5yearfollowupofaprospectivecohortstudy |